2024

1. 4CMenB journey to the 10-year anniversary and beyond

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

   Journal of Infectious Diseases, Vol. 229, pp. S112-S119

3. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

4. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

5. COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

6. Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein–Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study

   Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 9, pp. 2454-2467.e8

7. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

8. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

   The Lancet Infectious Diseases, Vol. 24, Núm. 8, pp. 817-828

9. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

   Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

10. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» (Archivos de Bronconeumología (2024) 60(3) (161–170), (S0300289624000061), (10.1016/j.arbres.2024.01.004))

    Archivos de Bronconeumologia

11. GUANIN: an all-in-one GUi-driven analyzer for NanoString interactive normalization

    Bioinformatics, Vol. 40, Núm. 8

12. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

13. How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?

    Influenza and other Respiratory Viruses, Vol. 18, Núm. 6

14. Interferon gene expression declines over time post-COVID infection and in long COVID patients

    Infectious Diseases

15. Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia

    Genes and Diseases, Vol. 11, Núm. 3

16. Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

    Emerging Microbes and Infections

17. New Vaccines for Chronic Respiratory Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 9, pp. 565-575

18. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

    The Pediatric infectious disease journal, Vol. 43, Núm. 5, pp. 444-453

19. Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 161-170

20. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study

    Pediatric Allergy and Immunology, Vol. 35, Núm. 5